Will AAV provide gene therapy with a safer, more efficient delivery vehicle?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
McKeon, C. and Samulski, R.J. 1996. Hum. Gene Ther. 7: 1615–1619.
Flotte. T. et al. 1996. Fed. Pulmonol., Suppl. 13: 275.
Wagner, J.A. et al. 1996. Ped. Pulmonol., Suppl. 13: 276.
Flotte, T. and Carter, B.J. 1995. Gene Therapy 2: 357–362.
Afione, S.A. et al. 1996. J. Virol. 70: 3235–3241.
Alexander, I.E. et al. 1994. J. Virol. 68: 8282–8287.
Ferrari, F.K. et al. 1996. J. Virol. 70: 3227–3234.
Fisher, K.J., et al. 1996. J. Virol. 70: 520–523.
Conrad, C.K. et al. Gene Therapy 3: 658–668.
Xiao X. et al. 1996. J. Virol. 70: 8098–8108.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carter, B. The promise of adeno-associated virus vectors. Nat Biotechnol 14, 1725–1726 (1996). https://doi.org/10.1038/nbt1296-1725
Issue date:
DOI: https://doi.org/10.1038/nbt1296-1725
This article is cited by
-
Macromolecular cytosolic delivery: Cell membranes as the primary obstacle
Archives of Pharmacal Research (1998)